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Morphologic criteria illustrated in WHO guidelines are the most significant prognostic factor in human gliomas, but novel
biomarkers are needed to identify patients with a poorer outcome. The present study examined the expression of the oncofetal
protein IMP3 in a series of 135 patients affected by high-grade (grade III and IV) gliomas, correlating the results with proliferative
activity, molecular parameters, and clinical and follow-up data. Overall, IMP3 expression was higher in glioblastomas (68%) than
in grade III tumors (20%, 𝑃 < 0.0001), and IMP3-positive high-grade gliomas showed a shorter overall and disease-free survival
than negative ones (𝑃 = 0.0002 and 𝑃 = 0.006, resp.). IMP3 expression was significantly associated with the absence of mutations
of IDH1 gene (𝑃 = 0.0001) and with the unmethylated phenotype of MGMT in high-grade gliomas (𝑃 = 0.004). High Ki67
levels were correlated with better prognosis in glioblastomas but IMP3 expression was not correlated with the proliferation index.
These findings confirm the role of IMP3 as a marker of poor outcome, also in consideration of its association with IDH1 wild-type
phenotype and MGMT unmethylated status. The data suggest that IMP3 staining could identify a subgroup of patients with poor
prognosis and at risk of recurrence in high-grade gliomas.
1. Introduction
The insulin-like growth factor II mRNA-binding protein
family comprises three proteins (IMP1, IMP2, and IMP3)
that regulate mRNA transport, translation, and turnover and
their function is implicated in cell proliferation, adhesion,
invasion, and migration [1].
Their expression is almost exclusively restricted to the
early stages of embryogenesis, and, in particular, IMP3 is
epigenetically silenced soon after birth, with little or no
detectable protein in normal adult tissues [2].
Its reexpression is observed in a wide spectrum of human
tumors, including ovarian, serous endometrial, and cervical
adenocarcinomas, as well as lung, pleural, gastric, colorectal,
renal, and bladder cancers and in lung tumors with neuroen-
docrine differentiation, but not in benign counterparts [3, 4].
In addition, IMP3 reexpression is correlated with tumor
aggressiveness and unfavorable prognosis and it is also
considered a marker of preinvasive lesions [5]. We recently
identified IMP3 as a biomarker for distinguishing atypical
premalignant endometriotic cysts from endometriotic cyst
with reactive changes [6].
Gliomas are the most common primary brain cancers in
adults, characterized, especially for higher grades, by poor
prognosis. The World Health Organization (WHO) identi-
fies three major glioma histotypes (astrocytoma, oligoden-
droglioma, and mixed oligoastrocytoma) graded according
to the neoplastic cellular density, number of mitotic figures,
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Table 1: Clinicopathological characteristics of patients enrolled in the study.
Grade Age (years) Gender (M/F) Ki67 values (%) MGMTmethylated cases IDH1R132H
III (𝑛 = 29) 49 (22–72) 15/14 7.8 (1–50) 19 (65,5%) 16 (55,2%)
IV (𝑛 = 106) 55 (24–78) 62/44 10 (2–75) 38 (39%) 11 (11,5%)
presence or absence of nuclear atypia, neovascularization,
and necrosis. This grading system, based exclusively on
morphology, is the most significant prognostic factor in
predicting glioma patients’ survival [7]. Moreover, even if it
is not included as a grading parameter in the current WHO
classification, the proliferative index, measured by Ki67
immunoreactivity, is commonly employed by pathologists to
support the diagnosis and to grade glioma [8, 9].
Molecular characteristics, including methylation of O6-
methylguanine-DNA methyltransferase (MGMT) promoter,
isocitrate dehydrogenase 1 or 2 (IDH1/2) gene mutations,
or 1p/19q chromosomal loci deletion, are currently used to
genetically classify glioma patients. Therapeutical strategies
commonly employed by neurooncologists include surgery
and radiotherapy but prognosis remains poor especially for
adult patients and for high-grade tumors [10–13]. Therefore,
novel biomarkers are needed to improve accuracy of histo-
logical diagnosis and to provide more accurate prognostic
information [14, 15].
Previous studies identified IMP3 as a glioblastoma-
specific marker and as a prognostic factor in series of
83 glioblastomas and in a series of 77 pediatric pilocytic
and pilomyxoid astrocytomas, though only in the latter
confirmed by multivariate analysis [16, 17].
Since the IMP3 expression in tumoral tissues has been
correlated with decreased survival and increased risk of
progression and metastases and Ki67 index is a parameter
that is helpful in grading gliomas, in this study we evaluated
IMP3 expression and Ki67 labeling index in a series of adult
patients with high-grade gliomas.
The aim of this study was to evaluate clinical significance
of the immunohistochemical expression of IMP3 in high-
grade gliomas and to investigate its role as a diagnostic and
prognostic biomarker.
2. Materials and Methods
2.1. Patients. We enrolled a series of 165 patients diag-
nosed with glioma that consecutively underwent surgery
for therapeutic purposes at Fondazione IRCCS Ca’ Granda
Hospital (Milan, Italy) between 2008 and 2011. The Hospital
Institutional Review Board approved the study. Gliomas
were diagnosed following theWHO classification. According
to these criteria, 10 and 19 patients were diagnosed as
anaplastic oligodendrogliomas (AO) or astrocytomas (AA),
respectively, (grade III) and 106 as glioblastomas (GBM,
grade IV).
Patients’ clinicopathological characteristics are detailed
in Table 1.
All the patients were treated with surgical resection of
the lesion. Extent of resection was evaluated on brain MRI
performed within 3 days after surgery. Gross total resection
(GTR) was defined as more than 95% of tumor volume
removed and could be obtained in fifteen (52%) grade III
glioma and in 70 (66%) GBM patients. Subtotal resection
(STR, corresponding to removal of 80–95% of the tumor)
and partial resection (PR, removal of less than 80% of the
tumor) were achieved in 6 (20%) and 8 (28%) grade III
patients, respectively. Nineteen (18%) GBM patients received
a STR and 8 (7,5%) a PR. MR imaging scans were read
blinded by neuroradiologists and surgeons (Manuela Caroli,
Andrea Di Cristofori, and Paolo Rampini) and postoperative
scans (contrast enhancement)were analyzed to determine the
extent of the resection. GBM patients had a median Karnof-
sky performance score (KPS) at diagnosis of 75 (range: 50–
100). Following histological diagnosis, all patients underwent
concomitant chemoradiation therapy according to Stupp’s
protocol.
Follow-up of patients consisted of neurooncological
assessment and brain MRI with gadolinium every 3 months.
Disease-free survival (DFS) was calculated from surgery to
tumor progression determined by radiological (brain MRIs)
procedures, whereas overall survival (OS) was calculated
from surgery to patients’ death. Follow-up ended in Decem-
ber 2012.
2.2.Molecular Characterization of Gliomas. Promotermethyla-
tion status of the O(6)-methylguanine-DNA methyltransfer-
ase (MGMT) gene was analyzed in all cases using the
CpGenome DNA Modification Kit followed by CpG-WIZ
MGMT-Methylation specific PCR assay (Millipore Corpo-
ration, Billerica, MA, USA) following manufacturer instruc-
tion.
2.3. Immunohistochemistry. Routinely prepared formalin-
fixed paraffin-embedded blocks were used to construct
6 paraffin-embedded tissue microarrays, as previously
described, with slight modifications [18]. Briefly, for this
series, we sampled one core of normal brain tissue and four
cores of tumor tissue for each case.
Onemmdiameter coreswere generated using a semiauto-
matic arrayer (Alphelys Minicore2, Plaisir, France) and each
tissue microarray block contained up to 165 cores with a total
of 980 spots, with 5 spots per case.
Before immunohistochemistry (IHC), analyses were per-
formed; a section from each tissue microarray block was cut
and stained with hematoxylin and eosin for morphological
evaluation.
All cells of each tissue core included in the TMAs were
evaluated, and only cases containing two or more preserved
tissue cores were scored.
IDH1 c.395G>Amutationwas investigatedusing IDH1R132H
mouse monoclonal antibody (clone H09, Dianova GmbH,
Hamburg, Germany) that has been demonstrated to be
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a reliable method for evaluation of this mutation status with
no false negative cases [19, 20].
IMP3 and Ki67 immunohistochemical expression were
evaluated by using IMP3 antibody (M3626), a mouse mon-
oclonal antibody specific for IMP3/KOC antigen (clone 69.1,
DAKO,Carpenteria, CA,USA), andKi67 antibody (MIB1) by
DAKO.
Immunohistochemistry was performed using the auto-
matic system BenchMark XT (Ventana Medical Systems,
Inc., Tucson, AZ, USA). Reactions were revealed using the
UltraViewTM Universal DAB, a biotin-free, multimer-based
detection system, according to the manufacture’s instruction.
Sections of pancreatic carcinoma known to express IMP3
were used as positive controls.
For negativeand positive controls, we replaced the primary
antibody with nonimmune IgG or we incubated a human
placenta with IMP3 antibody, respectively.
Positive staining for IMP3 was defined as a high intensity,
dark brown cytoplasmic staining in at least 10% of tumor cells
of the tissue microarray cores easily observed at low-power
magnification (10x) and was scored as focal (≤30%) or diffuse
(>30%). The scores from each core stained with IMP3 in the
same patient were averaged to obtain a mean value.
The percentage of Ki67-positive cells (Ki67 labeling
index) was scored in tumor hot-spots from four high-power
fields on full section slides. The highest Ki67 percentage in
each case was then recorded and used as proliferation index.
Immunohistochemical slides from all the cases were
blind-reviewed by three expert pathologists (Alessandro Del
Gobbo, Stefano Ferrero, and Lucia Ferrari).When discrepan-
cies occurred, the three pathologists reviewed the case to find
an agreement score.
2.4. Statistical Analysis. Groups’ comparisonswere performed
using univariate two-sided Student’s 𝑡-test or Mann-Whitney
𝑈 test when appropriate. The significance of a variable for
patients’ prognosis was analyzed using the Cox regression
hazard model as either univariate or multivariate analy-
sis (MedCalc Software, Mariakerke, Belgium) considering
proteins IHC score, MGMT methylation status, or tumor
grade as categorical variables. For Ki67 immunoreactivity
scores, cut-offs to separate patients into low- or high-
expressor groups were generated using receiver operating
characteristics (ROC) curves using the nonarbitrary criterion
derived from the Youden index (𝐽, MedCalc Software). The
𝐽 index is defined as sensitivity plus specificity minus 1. We
calculated the 𝐽 index on the merged series of patients for
which follow-up data were available (𝑛 = 94) and then we
separately applied it as cut-off on the grade III or grade IV
sets to consistently test the predictive effect of the variable
on different patients’ series. The Kaplan-Meier method was
used to plot survival curves when patients were categorized
into two groups based on the variable. In disease-free survival
analysis, patients’ death was censored. Difference in survival
curves was computed using the log-rank test or by Cox’s
proportional-hazards regression model (MedCalc Software).
Two-sided𝑃 values less than 0.05were considered statistically
significant.
Table 2: Immunohistochemical results.
Grade IMP3 (%) IMP3 score
III (𝑛 = 29) 6 (20%)5 AA; 1 AO
4/6 focal (66%)
2/6 diffuse (33%)
IV (𝑛 = 106) 74 (68%) 31/74 focal (42%)43/74 diffuse (58%).
3. Results
IMP3 expression could be evaluated in all 165 patients
affected by primary gliomas. All patients were treated with
surgical removal and nobody received a diagnostic-only
procedure. Disease-free survival data were available for 14
grade III (49%) and 64GBM patients (60%), respectively.
Conversely, overall survival data were available for 22 grade
III gliomas (76%) and 74GBMs (69%). IDH1 and MGMT
immunohistochemical and molecular profile were evaluated
in all grade III tumors and in 95 (90%) GMBs, respectively.
Overall, IMP3 expression was found in 74GBMs (68%)
and 6 grade III tumors (20%, 𝑃 < 0.0001). With regard to
grade III tumors, 5 out of 6 (84%) IMP3-positive gliomas
showed an astrocytic differentiation (Table 2). GBMs showed
a diffuse pattern of staining in 42 out of 74 positive cases (58%;
Figure 1), whereas grade III tumors displayed this staining
pattern in 2 out of 6 positive cases (33%; Figure 1).
We next investigated whether IMP3 expression could be a
prognostic marker for high-grade gliomas, and we found that
immunoreactive IMP3-HGG showed a shorter overall and
disease-free survival than IMP3-negative cases (𝑃 = 0.0002
and 𝑃 = 0.006, resp.; Figure 2(a)). This result was confirmed
analysing separately grade III (Figures 2(c) and 2(d)) or GBM
(Figures 2(e) and 2(f)) patients for disease-free or overall
survival times.
No difference was found when correlating focal or diffuse
IMP3 staining with disease-free and overall survival, and no
statistically significant correlations were observed with the
other demographic or clinicopatholagical parameters such as
age or sex.
Analysis of public database such as Oncomine (https://
www.oncomine.org/resource/login.html) or Rembrandt (http://
rembrandt.nci.nih.gov) for IMP3 (gene ID: IGF2BP3) gene
expression or gene amplification in human gliomas showed
that it was overexpressed by HGGs and specifically by GBM
(Table 3 and Figure 3(a)) and also correlated with poor prog-
nosis (Figure 3(b)), thus confirming our protein expression
data.
With regard to molecular characteristics, mutation of
IDH1 gene (R132H) as detected by immunohistochemistry
was more frequently present in grade III gliomas than in
GBMs (𝑃 < 0.0001 by Chi-square), and in GBMs its presence
was a favorable prognostic marker being associated with a
higher DFS and OS (𝑃 < 0.0001 and 𝑃 = 0.0001, resp.).
Methylation of MGMT gene promoter was more fre-
quently found in GBMs than in grade III gliomas (𝑃 <
0.0017 by Chi-square) and it was significantly associated with
better OS and DFS in GBM (𝑃 < 0.0001 and 𝑃 = 0.0001,
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Figure 1: IMP3 staining in HGGs. Representative images of negative, focally, or diffuse positive cytoplasmic staining are shown for GBM
or grade III glioma together with negative and positive (human placenta) controls. Original magnification for TMA spot is 40x. Scale bar
indicates 100 𝜇m.
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Figure 2: Cox proportional-hazards regression analyses of IMP3-positive and IMP3-negative HGGs for overall ((a), (c), and (e)) or disease-
free survival ((b), (d), and (f)). IMP3 presence is a poor prognostic factor either considering high-grade gliomas (𝑃 = 0.0002, HR: 0.3392,
95% CI: 0.1928–0.5965 and 𝑃 = 0.006, HR: 0.4586, 95% CI: 0.2631 to 0.7994 for OS and DFS, resp.) or separately grade III (𝑃 = 0.02, HR:
4.47, 95% CI: 1.19–16.8 and 𝑃 = 0.02, HR: 13.30, 95% CI: 1.44–122.6 for OS and DFS, resp.) and GBM (𝑃 = 0.01, HR: 0.41, 95% CI: 0.19 to 0.84
and 𝑃 = 0.04, HR: 0.5, 95% CI: 0.23–0.98 for OS and DFS, resp.) patients.
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Table 3: The Oncomine repository1 was queried for IMP3 (IGF2BP3) differential expression in brain cancers and only studies performed
on human tissues were considered. The name of the study, the samples for which the comparison was significant2, the relative expression
difference (fold change), and the associated 𝑃 value (𝑡 statistic provided within the database) are reported.
Study Comparison3 Analysis4 P value Fold change
TGCA brain OD versus normal brain GEX 1.65𝐸 − 30 7.03
Nutt brain GBM versus OD GEX 1.88𝐸 − 05 3.2
Sun brain
OD versus normal brain
GEX
1.63𝐸 − 26 9.07
OD versus normal brain 1.40𝐸 − 07 4.04
AA versus normal brain 6.70𝐸 − 05 3.2
Murat brain OD versus normal brain GEX 1.40𝐸 − 17 3.67
Liang brain GBM versus OD and mixed glioma GEX 7.80𝐸 − 07 2.2
Bredel brain 2 GBM versus brain cancers GEX 4.26𝐸 − 05 2.05
OD versus normal brain 6.48𝐸 − 04 4
Shai brain GBM versus brain cancers GEX 1.30𝐸 − 05 1.71
OD versus normal brain 6.02𝐸 − 06 1.78
TGCA brain 2
GBM versus brain cancers
CNV
6.07𝐸 − 53 1.2
OD versus normal brain 2.40𝐸 − 08 1.1
OD versus normal brain 1.20𝐸 − 150 1.3
Beroukhim brain OD versus normal brain CNV 4.30𝐸 − 11 1.14
GBM versus brain cancers 5.70𝐸 − 04 1.08
1https://www.oncomine.org/resource/login.html.
2
𝑃 value less than 1𝐸 − 4.
3GBM: glioblastoma; OD: oligodendroglioma.
4GEX: gene expression analysis; CNV: DNA copy number variation analysis.
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Figure 3: In silico analysis of IMP3 levels in human gliomas. The Rembrandt database was queried for IMP3 gene (IGF2BP3) expression
in gliomas and in nonneoplastic counterparts (a) or for correlation of IMP3 overexpression with GBM patients’ prognosis (𝑛 = 167GBM
patients) (b). Kaplan-Meier survival curves were generated for GBM with unchanged IMP3 expression (fold-change 0.8–1.2, intermediate
group, 𝑛 = 44) or overexpression (fold-change ≥5, high group, 𝑛 = 123). 𝑃 values are from log-rank test. Astr.: astrocytoma; OD:
oligodendroglioma; normal: nonneoplastic brain parenchyma; GBM: glioblastoma.
resp.), whereas it was not associated with other demographic
parameters such as age or sex.
IMP3 expression was significantly associated with the
absence ofmutations of IDH1 gene (𝑃 = 0.0001) (Figure 4(a))
and with the unmethylated phenotype ofMGMT (𝑃 = 0.004)
(Figure 4(b)) in HGG. No statistically significant difference
in survival was observed when comparing IMP3- and IDH1-
positive high-grade gliomas to IMP3-positive HGG with no
IDH1 mutation.
Next we tested whether IMP3 expression was correlated
with brain tumor proliferation, assessed by Ki67 antigen
expression. In astrocytomas, ultrarapid Ki67 immunostain-
ingwas demonstrated to be a useful adjunct tomorphological
diagnosis and grading, in particular in intraoperative diagno-
sis of gliomas [8]. Moreover, in anaplastic oligodendroglial
tumors, Ki67 index has been demonstrated to have a strong
prognostic impact [9].
Therefore, we correlated IMP3 expression to Ki67 levels
detected at diagnosis. Matched data were available for 105
patients, including 29 grade III and 76 grade IV gliomas.
GBMs expressed higher Ki67 levels compared to anaplastic
astrocytomas (𝑃 = 0.0014), but IMP3 expression was not
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Figure 4: Frequency charts that show association between IDH1 mutation (𝑃 = 0.0001, (a)) and MGMTmethylation status (𝑃 = 0.004, (b))
with IMP3 protein expression in high-grade gliomas.
correlated with the proliferation index in GBM and grade
III tumors. Higher Ki67 levels as determined by ROC curve
(𝐽 index: 0.38, criterion > 7, Figures 5(a) and 5(b)) were
correlated with longer DFS (𝑃 = 0.0007) and OS (𝑃 = 0.002)
in GBM patients (Figures 5(c) and 5(d)).
Finally, we analyzed the survival data in relation to the
extent of resection. GBM patients who received a GTR had
a better outcome, considering either overall or disease-free
survival (𝑃 < 0.0001 for OS and 𝑃 = 0.0001 for DFS).
Conversely, no statistically significant difference was iden-
tified for grade III gliomas. We therefore analyzed whether
IMP3 expression was an independent prognostic factor. In
multivariate analysis, IMP3 lost its prognostic significance,
whereas the extent of resection maintained its predictive
power (𝑃 = 0.0009, HR = 0.3, 95% CI: 0.15–0.60 by Cox
regression analysis).
4. Discussion
In this study,we examined IMP3protein expression in a series
of human gliomas, correlating our results with molecular
parameters and Ki67 proliferative index.
IMP3 is a member of the insulin-like growth factor
II mRNA-binding protein that regulates mRNA transport,
translation, and stabilization, and it is expressed during the
early phases of embryogenesis contributing to cell growth and
cell migration [1–3].
In particular, in nervous system, IMP3 has been demon-
strated in Xenopus laevis to be required for neural crest
migration, suggesting that this protein is important for
promoting cell migration [20].
After birth, IMP3 is epigenetically silenced, with no
detectable protein in normal adult tissues.
Several studies demonstrated that IMP3 is overexpressed
and plays a role in a wide spectrum of human malignancies
and its expression has potential utility in routine surgical
pathology practice by discriminating between high-grade
preneoplastic lesions and cancer in doubtful cases and pro-
viding prognostic information [1–3].
In particular, IMP3 is a useful tool for the diagnosis
of gastrointestinal (oesophageal, pancreatic, and biliary),
mesothelial, gynaecologic (endometrial serous and squa-
mous cervical), and neuroendocrine carcinomas [4], with
very high sensitivity and specificity for these cancers in
association with pathological and clinical data [21].
Regarding preinvasive lesions, we recently demonstrated
that IMP3 can help in discriminating endometriotic cysts
with reactive atypia from cysts lined by preneoplastic atypical
endometriosis [5].
As a prognostic marker, different studies demonstrated
that IMP3 can identify subgroups of patients affected by local-
ized renal cell carcinomas, superficial urothelial carcinomas,
and colorectal carcinomas with poorer prognosis [22].
The only previous study about IMP3 protein expression
in adult gliomas focused just on glioblastomas and identified
IMP3 as a GBM-specific marker of tumour aggressiveness
and of poor prognosis. The authors demonstrated that IMP3
action through IGF-2 results in the activation of oncogenic
PI3K and MAPK pathways [15].
Another protein of IMP-family, IMP2, has been demon-
strated toregulate oxidative phosphorylation in glioblastomas
sphere cultures, and its depletion resulted in impaired clono-
genicity and tumorigenicity in vitro [23].
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Figure 5: (a) Ki67 labeling indexwas scored inHGGs as the percentage of positive tumor cells in each case. AO: anaplastic oligodendroglioma;
AA: anaplastic astrocytoma; GBM: glioblastoma. ∗∗𝑃 < 0.01 by 𝑡-test. (b) ROC curvewas used to calculate a cut-off for patients’ categorization
according to Ki67 levels (𝐽 index). Disease-free survival (𝑃 = 0.0007, HR = 0.4, 95% CI: 0.2–0.9) (c) and overall survival (𝑃 = 0.002, HR =
0.4, 95% CI: 0.1–1.1) (d); end-points were evaluated in GBM patients according to Ki67 index using the Kaplan-Meier method. 𝑃 values are
from log-rank test.
In this context, our study, togetherwith in silico evidences,
demonstrates that IMP3 plays a role in glioma progression
and its elevated expression identifies a subset ofHGGpatients
with shorter survival times independently of the tumour
grade.
With regard to anaplastic gliomas (grade III), 84% of
IMP3-positive cases showed astrocytic differentiation and
we could speculate that IMP3 expression is more likely
associated with astrocytic lineage.
In relation to molecular characteristics of high-grade
gliomas, we correlated IMP3 protein expression with IDH1
mutational and MGMTmethylation status.
Epigenetic silencing of the MGMT DNA-repair gene by
promoter methylation compromises DNA repair and has
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been associated with longer survival in patients with glioblas-
toma who receive alkylating agents and temozolomide [24].
Recent studies confirmed that IDH1 mutation is associ-
atedwith better prognosis in patientswith gliomaby inducing
cell cycle arrest in G1 phase, inhibiting cell proliferation, and
reducing invasion ability, by reducing the levels of matrix
metalloproteinases MMP2 and MMP9 [25].
In our study, we investigated IDH1 mutational status
through the immunohistochemical antibody mIDH1R132H
according to the evidence of a statistically significant corre-
lation between the immunohistochemical staining and the
relevant mutation c.395G>A (p.R132H) [26].
Our findings showed that IMP3 protein expression was
also significantly associated with IDH1 wild-type phenotype
and MGMT unmethylated phenotype in HGG gliomas and
we can speculate that the expression of IMP3 in cases without
IDH1mutations andMGMTmethylation confirms the role of
the former as a negative prognostic marker.
We next studied whether this protein was related to
tumor proliferation using Ki67 expression, a nuclear anti-
gen expressed by cells at all cell cycle phases except G0.
According to scientific literature and WHO classification,
increasing values of Ki67 are correlated with increasing grade
of malignancy in human gliomas [8, 9, 27]. Ki67 staining
is helpful in differentiating between diffuse astrocytomas
and anaplastic astrocytomas, although it cannot discriminate
between grade III astrocytoma and GBM. In addition, there
is an important overlap of Ki67 values between the different
grades of gliomas and there are variations in the proposed
cut-off values between different studies. For these reasons,
it cannot be used as a diagnostic factor alone but should be
used in combination with WHO morphological established
criteria [28], or possibly in association with other immuno-
histochemical markers.
To investigate whether IMP3 could be one of these
markers, we looked for a correlation between IMP3 immuno-
histochemical expression andKi67 labeling index in the high-
grade gliomas. Although bothmarkers were overexpressed in
GBM patients compared to grade III gliomas, no significant
association between IMP3 and Ki67 could be identified.
In conclusion, this is the first study that investigates the
immunohistochemical expression of the IMP3 protein with a
correlation with other important parameters (IDH1mutation
and MGMTmethylation status) and Ki67 proliferative index
in a large series of high-grade gliomas. Our study documents
the association between this marker and patients’ prognosis
in these tumors.
The previous demonstration of IMP3 involvement in
PI3K pathway suggests that it could be a target for biological
therapies, in particular in combination with PI3K inhibitors,
which include more than fifteen drugs that have already
progressed in clinical trials [29].
Our results suggest that IMP3 staining could increase the
accuracy of histological diagnosis and tumor grading and
could identify a subgroup of patients with poor prognosis and
at a higher risk of recurrence in high-grade gliomas.
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